Spectrum for Diagnostic Industries (Joint Stock Company)

Spectrum for Diagnostic Industries specializes in in vitro diagnostic (IVD) reagents for clinical chemistry testing. Their portfolio includes liquid-stable reagents for measuring key biomarkers such as γ-glutamyltransferase (γ-GT/GGT), triglycerides, uric acid, and lactate. These products are formulated for laboratory use, with some variants designed as single reagents for targeted biochemical assays. The company’s focus is on high-quality diagnostic solutions to support clinical decision-making.

The company is headquartered in Egypt. Its IVD reagents are registered in the EU’s eudamed database, which is the official registry for medical devices authorized under EU regulations. This listing ensures transparency and compliance with EU requirements for in vitro diagnostics.

The company’s IVD reagents fall into different risk-based classification categories under EU regulations. Specifically, their products are classified as Class A (low risk) and Class B (moderate risk), as well as under the broader IVD General category. Classification is determined by factors like the intended use, potential health risks, and the nature of the diagnostic test, ensuring appropriate regulatory oversight.

The company’s reagents are designed for clinical chemistry testing, which involves analyzing biochemical substances in blood or other bodily fluids. Their products enable assays for critical markers like γ-glutamyltransferase (γ-GT/GGT), triglycerides, uric acid, and lactate, helping laboratories assess liver function, cardiovascular risk, metabolic health, and other clinical parameters. These tests are essential for diagnosing and monitoring various conditions.